COVID-19 ANTIBODY HOME TESTING KIT (PREVIOUS EXPOSURE)

PRICE £65.00

Quantity

Postal IgG/IgM Total Antibody Test

  • Test for evidence of the immune response to COVID-19
  • Results within 48-72 hrs of postage
  • Finger-prick test, taken at home, at your convenience

PRICE: £65 + £15 Postage

At Home Covid-19 (Anti-SARS-CoV-2-S Spike) IgG/IgM Total Antibody Test

This is a test for the quantitative determination of antibodies against the SARS-CoV-2 in serum. The spike protein is the target of many Covid-19 vaccines in development. This blood test enables determination of both the presence and level of antibodies to the Covid spike protein. This test can signal whether a person has already been infected and has potentially started to develop a level of immunity to the virus. 

 

Antibody tests look for evidence of the immune response to covid-19. The aim to answer the question: have I been exposed to COVID-19 and produced an immune response? You can read in more detail about the types of test here. If you want to see if you are carrying Covid-19 now, you need to use an antigen test (PCR test)

We do not yet know if the antibodies are protective to make you immune and we do not yet know how long this immunity will last. 

Testing should be undertaken 14 days or more following exposure, onset of symptoms or post-vaccination. The incubation period of COVID-19 ranges from between 1 to 14 days, with the majority of cases manifesting with symptoms at 3–5 days.

If an individual has been infected with SARS-CoV-2, they may have detectable antibodies to both the nucleocapsid (N) and the spike protein receptor binding domain (RBD). Baseline antibody tests for both nucleocapsid and RBD antigens are therefore helpful to identify patients who have been previously infected with SARS-CoV-2. It is not yet known if an individual with a positive result showing presence of IgG levels following being infected with SARS-CoV-2 will be protected, either fully or partially from future infection, or for how long protective immunity may last.

If an individual has been vaccinated against SARS-CoV-2, with no history of natural infection, the antibodies they develop are to the spike protein receptor binding domain. Determining the levels of these antibodies could play a role in establishing vaccine efficacy and vaccine-induced immune response.

The laboratory we work with offers 4 assays for the detection of antibodies targeted against SARS-CoV-2. All the tests are CE marked and registered for use in the UK. The assay we select with the laboratory by default is the  Anti-SARS-CoV-2-S (Spike) IgG/IgM total antibody test. The other available assays are:

Anti-SARS-CoV-2 IgG/IgM total antibody test

This blood test enables the determination of the presence of IgG and IgM antibodies to the SARS-CoV-2 nucleocapsid protein.

SARS-CoV-2 IgG test

This blood test enables the determination of the presence of IgG antibodies to the SARS-CoV-2 nucleocapsid protein.

SARS-CoV-2 IgM test

This blood test enables the determination of the presence of IgM antibodies to the SARS-CoV-2 spike protein.

You can see a summary of the different assays below. 

 

Roche Elecsys
Anti-SARS-CoV-2 S
(Spike) Total antibody NEW

Roche Elecsys
Anti-SARS-CoV-2
Total Antibody

Abbott
Architect SARS-CoV-2
IgG

Abbott
Architect SARS-CoV-2
IgM

Platform

Roche e801

Roche e801

Abbott Architect

Abbott Architect

Assay type

Electrochemiluminescence immunoassay (ECLIA)

Electrochemiluminescence immunoassay (ECLIA)

Chemiluminescent Microparticle Immunoassay (CMIA)

Chemiluminescent Microparticle Immunoassay (CMIA)

Reporting format

QUANTITATIVE

Qualitative

Qualitative

Qualitative

Reporting ranges

Positive with value reported in U/ml / Negative

Positive / Negative

Positive / Negative

Positive/Negative

Antigen used

Spike protein receptor binding domain (RBD)

Nucleocapsid

Nucleocapsid

Spike protein

Analyte target

SARS-CoV-2 Antibodies (IgG/IgM) Total antibodies

SARS-CoV-2 Antibodies (IgG/IgM) Total antibodies

SARS-CoV-2 Antibodies (IgG)

SARS-CoV-2 Antibodies (IgM)

Sample type verified

Serum – venous or capillary self-collection

Serum – venous or capillary self-collection

Serum – venous

Serum – venous

Sensitivity

99.8%

97.4%

97.5%

96.67% in samples taken more than 14 days post symptoms onset

Specificity

98.8% in samples taken 14 days or later after positive PCR

100%

99.1%

99.0%

Seasonal Corona
Virus panel

24/24 Negative

26/26 Negative

26/26 Negative

N/A

Results should be used in conjunction with information available from  clinical evaluation and other diagnostic procedures. It has been recognised that there can be delayed responses in immunocompromised patients.

 

Please note that the antibody tests were developed for use and have been validated on venous blood samples (blood taken from a vein by a medical professional) rather than samples of blood taken from a finger-prick. This may affect the accuracy of the test. This is why, although we recognise the convenience of a home test, we would recommend that a medical professional takes your blood sample, which can be done at home or in the clinic.

TAKING THE TEST AT HOME

Finger-prick devices are supplied in the home testing kit that is delivered safely to your address. There are clear instructions about how to obtain the blood sample included in the box. Follow the instructions carefully and then simply place the box in the prepaid envelope included and post at any postbox.

This is part of a clinical service.

Our clinical service includes a full explanation of your results which will accompany your email containing your results. Expect to obtain results within 48-72 hrs of postage.